2022-003618-35: A study to determine the best dose, the efficacy, and safety of mocravimod in patients with large B cell lymphoma treated with genetically modified immune cells (CD19 CAR T cells) |
|
|
| Not yet recruiting | 1/2 | 30 | Europe | mocravimod, KRP203, Capsule, hard | Priothera S.A.S., Priothera S.A.S. | Patients with large B cell lymphoma treated with a CD19 CAR T therapy, Patients with large B cell lymphoma treated with a CD19 CAR T therapy, Diseases [C] - Cancer [C04] | | | | |
